Non-Current Assets
Equity Securities (FV-NI and No Readily Determinable FV)
Gilead Sciences Equity Securities (FV-NI and No Readily Determinable FV) decreased by 0.9% to $8.83B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 8.4%, from $8.14B to $8.83B. Over 2 years (FY 2023 to FY 2025), Equity Securities (FV-NI and No Readily Determinable FV) shows an upward trend with a 16.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
First reportedQ4 2023
Last reportedQ1 2026May 7, 2026
Metric ID:
equity_securities_fvni_no_fvHistorical Data
10 periods
| Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.55B | $4.04B | $3.66B | $5.89B | $10.79B | $8.14B | $5.57B | $8.34B | $8.91B | $8.83B |
| QoQ Change | — | -38.4% | -9.4% | +61.1% | +83.1% | -24.5% | -31.7% | +49.9% | +6.8% | -0.9% |
| YoY Change | — | — | — | — | +64.8% | +101.8% | +52.2% | +41.6% | -17.4% | +8.4% |
Range$3.66B – $10.79B
CAGR+14.2%
Avg YoY Growth+41.9%
Median YoY Growth+46.9%
Frequently Asked Questions
- What is Gilead Sciences's equity securities (fv-ni and no readily determinable fv)?
- Gilead Sciences (GILD) reported equity securities (fv-ni and no readily determinable fv) of $8.83B in Q1 2026.
- How has Gilead Sciences's equity securities (fv-ni and no readily determinable fv) changed year-over-year?
- Gilead Sciences's equity securities (fv-ni and no readily determinable fv) increased by 8.4% year-over-year, from $8.14B to $8.83B.
- What is the long-term trend for Gilead Sciences's equity securities (fv-ni and no readily determinable fv)?
- Over 2 years (2023 to 2025), Gilead Sciences's equity securities (fv-ni and no readily determinable fv) has grown at a 16.7% compound annual growth rate (CAGR), from $6.55B to $8.91B.